CJC-1295 vs Ipamorelin: Which to Pick, and Why the Community Runs Both (2026)
This is the unusual comparison where the honest answer to "which one" is usually "both, together." CJC-1295 and ipamorelin act on two different arms of the same growth-hormone system, and they are designed to be complementary rather than competing, which is why most people who research one end up running the pair, a pairing that anchors many of the most-tracked peptides for muscle growth. If you are forced to choose a single starting compound, ipamorelin is the gentler, more self-contained pick and CJC-1295 is the amplifier you add to it. But the framing that matters most is not "versus" at all.
Most "CJC-1295 vs ipamorelin" pages line up two columns and ask you to choose. We add the signal no competitor has: among ProtocolPlus users who track either peptide, how many run both at once, which direction the rare switchers actually move, and how the day-to-day tolerability compares in real reports. The mechanism explains why they belong together; the community data shows that people treat them that way. For the full science on either peptide, we link up to its dedicated guide so this page stays a clean decision hub and does not re-teach each molecule from scratch.
Head-to-head
Edge: Ipamorelin — by a modest margin
This is the rare head-to-head where the honest answer is usually 'both.' CJC-1295 (a GHRH analog) and ipamorelin (a selective ghrelin-receptor agonist) act on two different arms of the same growth-hormone axis, and in ProtocolPlus community data they are overwhelmingly run together rather than swapped: about 55% of people who track either also track both, and the net switch between them is essentially flat (~0.95:1). The moat panel leads with that co-tracking signal; the fit-score radar is the secondary editorial 'why,' where ipamorelin edges ahead only on tolerability (a slim 57 vs 53) while the two tie on evidence, effectiveness, accessibility, speed, and cost. Neither is FDA-approved and neither has human efficacy trials, so every figure here is pharmacology plus illustrative usage data, not proof.
Overall fit score
By dimension
Side by side
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Drug class / mechanism | GHRH analog (raises GH baseline via the GHRH receptor) | Selective GHRP / ghrelin-receptor agonist (triggers GH pulses) |
| Half-life | No-DAC (Mod GRF 1-29) ~30 min; with-DAC ~6-8 days | ~2 hours |
| DAC vs no-DAC | Two forms: with-DAC (long-acting, fewer injections) or no-DAC (short, pulsatile) | Single form (no DAC variant) |
| Route | Subcutaneous injection | Subcutaneous injection |
| Typical research-use dose framing | Studied/used at ~100 mcg per dose (no-DAC, 1-3x daily); not a recommendation | Studied/used at ~100-300 mcg per dose (1-3x daily); not a recommendation |
| Community cost per dose (illustrative) | ~$2.12 (vial ~$25-60, ~20 doses) | ~$1.60 (vial ~$25-55, ~25 doses) |
| Headline side effect (community reports) | Water retention ~14%, injection-site reaction ~16% | Water retention ~9%, injection-site reaction ~14% (gentler) |
| FDA status | Not FDA-approved; research compound, no human efficacy trials | Not FDA-approved; research compound, no human efficacy trials |
Educational. These are research compounds, not FDA-approved, with limited or no human trial data; this is not medical advice and not a claim that either is effective or safe. Community usage/switch figures are illustrative ProtocolPlus app data. Verify everything with a clinician.
Key Takeaways
- It is usually a stack, not a face-off. In ProtocolPlus data about 55% (roughly 898 users) of people who track either peptide track both. CJC-1295 plus ipamorelin is the canonical growth-hormone pairing, run together far more than swapped.
- They do different jobs. CJC-1295 is a GHRH analog that raises the baseline of GH release; ipamorelin is a selective ghrelin-receptor agonist (a GHRP) that triggers clean GH pulses. One sets the level, the other pulls the trigger.
- The "switch" is essentially flat. Among the rare solo users who move, the net is near zero: about 15% of CJC-1295 users (115) added or moved to ipamorelin, vs about 14% of ipamorelin users (121) the other way (~0.95 to 1). App data, a usage signal, not proof either is better.
- If you must pick one: ipamorelin is the better-tolerated solo choice (less water retention, ~9% vs ~14%; selective, with minimal cortisol or prolactin impact). CJC-1295 alone does little without a GH-releasing partner.
- CJC-1295's defining variable is DAC. With-DAC has a ~6 to 8 day half-life (fewer injections, steady action); no-DAC (Modified GRF 1-29) is short (~30 min) and pulsatile. Ipamorelin's half-life is ~2 hours.
- Both are research compounds, not FDA-approved, with no human efficacy trials. Cost is close and low per dose (ipamorelin ~$1.60 vs CJC-1295 ~$2.12 in our data).
CJC-1295 vs ipamorelin at a glance
Here is the side-by-side before we go deep. The single most useful thing to notice is that the two rows almost never make the same compound "lose," because they answer different questions: CJC-1295 owns the half-life and dosing-frequency story, ipamorelin owns tolerability. Everything below this table explains the why.
| Dimension | CJC-1295 | Ipamorelin |
|---|---|---|
| Drug class | GHRH analog (raises GH baseline) | Selective GHRP / ghrelin-receptor agonist (triggers GH pulses) |
| Half-life | No-DAC ~30 min; with-DAC ~6 to 8 days | ~2 hours |
| DAC variant | Yes, two forms (with-DAC long-acting; no-DAC short) | No (single form) |
| Route | Subcutaneous injection | Subcutaneous injection |
| Studied/used dose framing | ~100 mcg/dose (no-DAC), not a recommendation | ~100 to 300 mcg/dose, not a recommendation |
| Community cost / dose | ~$2.12 | ~$1.60 |
| Water retention (community) | ~14% | ~9% |
| FDA status | Research compound, not approved | Research compound, not approved |
The table looks like a list of small differences, and that is the point. The places the answer genuinely flips are half-life/dosing cadence (CJC-1295's call, via DAC) and tolerability (ipamorelin's edge). For most goals, the larger truth is that you are looking at two halves of one stack.
The signature insight: this is a stack, not a versus
This is the part no trial and no competitor column can give you: among users who have logged either peptide, how many run them together? The short version is that the great majority do. Mechanistically, that is not a coincidence or a marketing upsell, it is the whole design. CJC-1295 lifts the underlying amount of growth hormone the pituitary is willing to release, and ipamorelin provides the clean, selective pulse that releases it. Used alone, each does roughly half the job. Used together, they hit two distinct receptors on the same pathway, and the GH response is widely described as synergistic rather than simply additive.
Three numbers carry the story, all from ProtocolPlus app data among the roughly 1,632 users tracking one of these two peptides:
- Co-tracking: ~55% (about 898 users) run both. This is the headline. More than half of everyone who touches either peptide is on the stack, not on one in isolation. "CJC-1295 vs ipamorelin" is, in practice, mostly a question about which to add first.
- Adoption split: ~53% ipamorelin, ~47% CJC-1295. When people do track a single one, ipamorelin is the slightly larger solo camp (864 vs 768 users), consistent with it being the better-tolerated standalone choice.
- Net switch is essentially flat (~0.95 to 1). About 15% of CJC-1295 users (115) later added or moved to ipamorelin, versus about 14% of ipamorelin users (121) the other way. The net is roughly six users, statistically a wash. Nobody is fleeing one for the other; they are completing a stack.
Which way the few solo switchers move (and why it is a wash)
The balanced flow is the tell. In a real winner-takes-most matchup, you see a lopsided exodus toward the stronger option, the way some other peptide pairs behave. Here the traffic is near-symmetric because the typical "switch" is not abandonment, it is a solo user adding the second half of the stack. Someone who started on ipamorelin for tolerability later adds CJC-1295 to lift the baseline; someone who started on CJC-1295 adds ipamorelin for the pulse. Both directions are people converging on the same destination from opposite starting points. That is the cleanest possible evidence that the right mental model is "stack," not "rivalry."
How they work: two halves of the GH axis
The one-sentence answer: CJC-1295 tells the pituitary to make more growth hormone available, and ipamorelin tells it to release a pulse, so they act on two different receptors on the same pathway. That single fact explains every downstream difference in this comparison, including why the community stacks them.
Growth hormone is not secreted in a steady stream. The pituitary releases it in pulses, governed in large part by two upstream signals: growth-hormone-releasing hormone (GHRH), which stimulates release, and ghrelin, which amplifies the pulse through its own receptor (the GHSR). CJC-1295 is a synthetic GHRH analog: it mimics the GHRH signal, so it raises the overall amount of GH the pituitary will put out. Ipamorelin is a synthetic ghrelin mimetic, a growth-hormone-releasing peptide (GHRP): it binds the ghrelin receptor and triggers a clean, selective pulse. Hit both levers at once and you get a larger, more natural GH release than either produces alone, which is the standard pharmacological rationale for the pairing.
The crucial honesty check: this mechanism is well-described in pharmacology, but it has not been turned into proven human outcomes for either compound. There are no published Phase-3 efficacy trials showing that CJC-1295 or ipamorelin produces a specific clinical result in people. What exists is receptor pharmacology, animal data, and short human studies of GH and IGF-1 response. Treat the mechanism as the reason people use them, not as proof they deliver a benefit. For the deeper molecular detail on each, see the CJC-1295 guide and the ipamorelin guide.
One detail that genuinely separates them, and the reason ipamorelin earned its reputation, is selectivity. Older GHRPs (such as GHRP-6 and GHRP-2) tended to spill over into raising appetite, cortisol, and prolactin. Ipamorelin was developed to be highly selective for GH release with minimal effect on cortisol and prolactin, which is the pharmacological basis for it being considered the cleaner, better-tolerated GHRP. CJC-1295, as a GHRH analog, sits on a different receptor entirely and does not carry the classic GHRP appetite/cortisol concerns, though its long-acting DAC form raises a separate question discussed next.
The DAC question: CJC-1295's defining choice
The one-sentence answer: the single biggest decision inside CJC-1295 is not "versus ipamorelin," it is "with DAC or without," because that one variable changes the half-life from about half an hour to roughly a week. This is where most of the real CJC-1295 complexity lives, and competitor pages often skip it.
CJC-1295 comes in two forms. The no-DAC version (often sold as Modified GRF 1-29, or CJC-1295 without DAC) has a very short half-life, on the order of 30 minutes, so it produces a brief, pulse-like GHRH signal that pairs naturally with ipamorelin's own short action. The with-DAC version is bonded to a Drug Affinity Complex that lets it bind albumin and circulate for roughly 6 to 8 days, so a single injection keeps GHRH stimulation elevated for days. That convenience (fewer injections) comes with a trade-off that thoughtful users weigh: a continuous, days-long GHRH signal moves away from the body's naturally pulsatile GH pattern, which is the opposite of what the short-acting peptides are trying to preserve. Ipamorelin, by contrast, has no DAC variant and a half-life around 2 hours, so it is inherently the short, pulsatile partner. None of these numbers is a dosing instruction; they describe pharmacology, not a protocol.
The practical upshot is that "no-DAC CJC-1295 plus ipamorelin" is the combination most aligned with the natural pulsatile pattern, which is why it is the classic stack many people describe. The with-DAC form is mostly a convenience play for those who want far fewer injections and accept the trade-off in pulsatility. If you only remember one thing about CJC-1295, make it this: the DAC choice matters more than the choice between CJC-1295 and ipamorelin.
Tolerability: ipamorelin's clearest edge
The one-sentence answer: both are generally described as well tolerated, but in our community reports ipamorelin is consistently the gentler of the two across every tracked effect. These are self-reported community frequencies, not trial incidence and not proof of cause, but the pattern is steady rather than noisy.
In ProtocolPlus reports the most common effects line up like this: injection-site reaction (CJC-1295 16% vs ipamorelin 14%), water retention (14% vs 9%), numbness or tingling (12% vs 8%), headache (10% vs 8%), and increased hunger (8% vs 6%). Ipamorelin is more tolerable on every row, and the gap is widest on water retention, which fits the pharmacology: GHRH-driven, sustained stimulation (especially the DAC form) is more associated with fluid retention than ipamorelin's short selective pulse. The hunger difference is also expected, since ipamorelin's selectivity was specifically engineered to avoid the strong appetite stimulation seen with older GHRPs.
Because both raise growth hormone, both share the same theoretical class concerns that apply to any GH-axis compound: potential effects on insulin sensitivity and blood glucose, and the general caution that long-term human safety simply has not been established. For the complete tolerability breakdown and red-flag list, read CJC-1295 side effects and ipamorelin side effects. This page does not duplicate them.
Cost: close, low, and rarely the deciding factor
The one-sentence answer: per dose the two are within roughly fifty cents of each other in our community data, so cost almost never decides this matchup. Ipamorelin runs slightly cheaper, but both are inexpensive per dose compared with prescription GH-axis drugs.
In ProtocolPlus cost figures, ipamorelin runs about a median $1.60 per dose versus about $2.12 for CJC-1295, with vials in a similar $25 to $55-60 range. The small gap mostly reflects doses per vial rather than a real affordability story. The far larger cost variable is not which peptide you pick, it is whether you run the with-DAC or no-DAC CJC-1295 form (DAC means fewer injections per week) and, of course, that you are buying unregulated research-grade material whose price and quality vary widely by source. We do not quote vendor names or treat any of this as a buying guide; the per-dose figures are a directional signal, not a quote.
Speed and what to expect
The one-sentence answer: neither is a quick fix, both work on the GH axis over weeks to months, and "which works faster" is largely a myth at the peptide level. Any acute GH or IGF-1 bump from a single dose is just pharmacology; a felt change is a longer process and is not well documented in humans for either compound.
What people commonly describe (sleep quality, recovery, body-composition shifts) is reported over weeks, not days, and is heavily confounded by training, sleep, and diet. Crucially, because the two act on different receptors, "speed" is not really a head-to-head dimension: the short-acting pair is used precisely so the GH pulse rises and falls naturally, while the DAC form trades that pulsatility for convenience. If your goal is to mimic the body's natural rhythm, that is a point for the short forms together, not for either peptide as a solo speed winner.
The editorial scorecard (the "why," not a verdict)
The fit-score radar below rates each peptide 1 to 5 on six dimensions. With equal weighting the two are close, with ipamorelin edging ahead 57 to 53: they tie on evidence, effectiveness, accessibility, speed, and cost, and the only separation is safety/tolerability, where ipamorelin scores higher. That near-tie is the honest summary, and it is exactly what you would expect from two peptides built to complement each other rather than compete. The co-tracking data above, not this radar, is the headline signal.
Choose CJC-1295 if... / Choose ipamorelin if...
The honest framing is that most people end up running both, so read these as "which to start with or emphasize," not as a permanent fork.
Lean CJC-1295 if:
- You want the GH-baseline amplifier and value fewer injections (the with-DAC form can be dosed once or twice weekly).
- You already have a GH-releasing trigger and are completing the classic GHRH plus GHRP stack.
- You prioritize sustained, steady action over closely tracking the body's natural pulses.
- Remember: CJC-1295 alone does relatively little without a GH-releasing partner, so it is rarely a true solo pick.
Lean ipamorelin if:
- You want the best-tolerated single peptide: selective action, minimal cortisol or prolactin impact, and less water retention in our data (~9% vs ~14%).
- You prefer short, on-demand pulses that track the body's natural GH rhythm.
- You are cautious about side effects and want the gentler starting point.
- Remember: it lifts pulse height but not the GH baseline, so many people eventually add a GHRH partner.
The honest verdict
For most people the real answer to "CJC-1295 vs ipamorelin" is that it is the wrong question: they are two halves of the same growth-hormone stack, and the community runs them together about 55% of the time, with a switch flow so balanced it is effectively a wash. If you genuinely must choose one to begin with, ipamorelin is the gentler, more self-contained starting point, and CJC-1295 (ideally no-DAC, for pulsatility) is the amplifier you add to it. The bigger decision within CJC-1295 is DAC versus no-DAC, which changes its half-life from minutes to a week. And the most important caveat outranks all of it: neither peptide is FDA-approved, neither has human efficacy trials, and everything here is mechanism plus usage data inside a clinician-supervised plan, not a result you should expect or a protocol to run alone.
To make it concrete, here is how the decision usually lands by situation:
- Building the standard GH stack: run both, typically no-DAC CJC-1295 plus ipamorelin, for a pulse-like pattern.
- Forced to pick one to start: ipamorelin, the better-tolerated standalone.
- Want fewer injections and accept less pulsatility: with-DAC CJC-1295.
- Most sensitive to water retention or side effects: ipamorelin (~9% vs ~14%).
- Tightest budget: ipamorelin per dose (~$1.60 vs ~$2.12), though the gap is small.
- Worried about appetite or cortisol: ipamorelin, engineered for selectivity over older GHRPs.
For adjacent comparisons, see sermorelin vs ipamorelin and ipamorelin vs MK-677. For the full science on each molecule, see the CJC-1295 guide and the ipamorelin guide.
Frequently Asked Questions
Sources
- Teichman SL, Neale A, Lawrence B, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799-805. Retrieved 2026-06-18. https://academic.oup.com/jcem/article/91/3/799/2843324
- Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998;139(5):552-561. Retrieved 2026-06-18. https://academic.oup.com/ejendo/article/139/5/552/6754555
- Sinha DK, Balasubramanian A, Tatem AJ, et al. "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males." Translational Andrology and Urology, 2020;9(Suppl 2):S149-S159. Retrieved 2026-06-18. https://tau.amegroups.org/article/view/35251/html
- Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." Journal of Clinical Endocrinology & Metabolism, 2006;91(12):4792-4797. Retrieved 2026-06-18. https://academic.oup.com/jcem/article/91/12/4792/2656516
- U.S. Food & Drug Administration. "Certain Bulk Drug Substances for Use in Compounding (peptide review; CJC-1295 and ipamorelin are not FDA-approved drugs)." Retrieved 2026-06-18. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- ProtocolPlus. "Community head-to-head data: CJC-1295 vs ipamorelin" (head-to-head/cjc-1295__ipamorelin.json). First-party app data, 2026. n ~ 1,632 users tracking one of the two. Usage and switching signal, not a clinical efficacy verdict.